David F. Tough

R&d
Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity In Vivo.

Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity In Vivo.

Journal: Journal of medicinal chemistry

Published: June 22, 2026

The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis.

The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis.

Journal: Research square

Published: December 03, 2025

The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis.

The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen-Specific CD4 T Cells in Rheumatoid Arthritis and Health.

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen-Specific CD4 T Cells in Rheumatoid Arthritis and Health.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 06, 2025

CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders.

CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune Disorders.

Journal: Biomedicines

Published: April 24, 2024

The Epigenetic Reader Protein SP140 Regulates Dendritic Cell Activation, Maturation and Tolerogenic Potential.

The Epigenetic Reader Protein SP140 Regulates Dendritic Cell Activation, Maturation and Tolerogenic Potential.

Journal: Current issues in molecular biology

Published: April 17, 2023

Therapeutic opportunities for regulatory T-cell enhancing approaches.

Therapeutic opportunities for regulatory T-cell enhancing approaches.

Journal: Clinical and experimental immunology

Published: January 24, 2023

Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Journal: British journal of clinical pharmacology

Published: January 17, 2022

Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140.

Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140.

Journal: BMC biology

Published: October 27, 2021

Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation.

Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation.

Journal: Nature genetics

Published: August 04, 2021

Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation.

Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation.

Journal: Nature genetics

Published: August 04, 2021

Robust temporal map of human in vitro myelopoiesis using single-cell genomics.

Robust temporal map of human in vitro myelopoiesis using single-cell genomics.

Journal: Nature communications

Published: July 07, 2021

Showing 1-12 of 43

Last Updated: 09/26/2026